For example, patients with EGFR-mutant NSCLC are at a six-fold higher risk of NE conversion if they possess pre-existing RB1 and p53 mutations [150], suggesting these may not be appropriate candidates for combined therapies using EGFR and YAP/TEAD inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.